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1 INTRODUCTION 
 
1.1 Problem description  
The increased importance of software in healthcare justifies stricter regulatory oversight 
by governments, mainly safeguarding patient’s rights and establishing the essential prin-
ciples and limitations in which software in healthcare operates. 
International medical software suppliers need to meet regulatory requirements from 
different countries to gain market access and offer compliant solutions. There is a short-
age of methods and tools available to allow software suppliers to evaluate which software 
products to sell in which countries. In order to bridge the gap in method approach and 
tool availability, the research conducted in this report focuses on three main questions.  
• How to stay in compliance with regulatory requirements and export controls 
during the product lifecycle for medical software? 
• How to present the regulatory regional information during the product lifecycle 
to the various stakeholders? 
• How to organize the business to ensure delivery of value-added solutions with 
timely market access? 
By following these questions, the aim of the research is to offer the groundwork for a 
healthy practice on how to bring medical software products to the market while paying 
attention to all the relevant stakeholders involved.  
1.2  Literature 
Technology plays a significant role in the management of healthcare services. 
Healthcare informatics and Enterprise Resource Planning (ERP) systems claim to support 
the evolution in healthcare services by interconnecting data and records, providing a firm 
foundation for quality improvement in healthcare services and outcomes (Kolodner, 
2008).  
Software companies started considering development scenarios, at the intersection of 
medical informatics, public health, and business. The information delivered through com-
munications systems enhances the healthcare practice by adding the complexity needed 
for the medical act (Eysenbach, 2001).  
According to the research, performed by Radley(2013) the reason to push for 
healthcare informatics and eHealthcare is to reduce the risk of making medication errors 
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and to provide appropriate care paths for patients. Considering the nature of information 
and procedures involved in patient monitoring, diagnosis and treatment healthcare soft-
ware are classified as a safety-critical software. One wrong recommendation, medication 
flaw, or treatment error can put the patient’s life at risk. The demand for clinical decision 
support systems increases and software companies want to serve this market by offering 
relevant compliant solutions. Healthcare information systems and coordination of 
healthcare professionals through Information & Technology (IT) provide the interdisci-
plinary cross-department exchange of information improving clinical decision quality 
(Middleton, 2016) and consumer satisfaction (Eysenbach, 2001).  
The essential requirements checklist for eHealthcare software development and imple-
mentation must contain clear practices defining the following aspects:  
• Security 
• Privacy 
• Regulatory 
• Required Language 
• Support 
• Hosting 
• Software 
• Hardware 
• Labeling - instructions of use 
• Technical documentation 
• Medical definitions 
• Risk profile  
Healthcare organizations are struggling with developmental issues when addressing 
healthcare informatics and ERP implementation. Information Systems (IS) implementa-
tion in Healthcare need continuous improvement on confidentiality, integrity, privacy, 
and patient trust. Ensuring end-to-end security and privacy procedures in healthcare in-
formatics is a mandatory consideration. Security and privacy should be internal at every 
level in the process. This, by starting from the point of data collection through various 
sensor and mesh-networks, integration of internet of things, and continuing with the in-
frastructure communication links, data storage, access management, and enterprise gov-
ernance (Sahi et al., 2017).  
Security and privacy are important aspects of the essential requirements checklist and 
regard healthcare organizations end-to-end. The consequence of this consideration is that 
security and privacy by design become a mandatory practice in the process of creating 
medical software.  
Hospitals gain extensive amounts of information and data from several assets and de-
partments. An integrated system, such as an ERP system, allows health organizations to 
improve service efficiency and the quality of care by better managing information coming 
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from various services and processes (Handayani et al. 2013). Electronic healthcare rec-
ords, as well as healthcare process data, represent high-value information according to 
the data subject. From the patient perspective the security and privacy issue become an 
important aspect  (Sahi et al., 2017).  
Most research in healthcare informatics addresses the implementation of information 
systems, care coordination, and patient/doctor platforms. The research includes infor-
mation systems security and risk management (ISSRM) practices that safeguard sensitive 
data and assets in healthcare (Mucheleka, 2015). 
Addressing security and privacy concerns for healthcare organizations requires com-
bined ISSRM with hospital enterprise architecture (EA) framework principles. The 
framework principles are access control, authentication, non-repudiation, and accounta-
bility, segregation of duties, gate control without which end-to-end security and privacy 
cannot be ensured (Sahi et al., 2017).  
General-purpose healthcare informatics mostly is handled by generic health ERP sys-
tems. However, it is advisable to use service-oriented architecture (SOA) applications. 
SOA applications are not part of the standard implementation of ERP. SOA applications 
are developed for more specific purposes in healthcare. The EA literature enforces the 
development of microservices and applications using SOA because this is highly benefi-
cial to the system development process (Joyce, 2017). To ensure the end-to-end integrity 
and coherence around sensitive patient data, by adding software aplications to the overall 
ERP healthcare information system, ISSRM frameworks also need to be aligned for the 
SOA developed aplications (Mayer, 2018). 
End-to-end implementation of healthcare ERP systems have by design ISSRM frame-
works built in. Because of the specificity of certain healthcare activities, microservices 
and applications have to be implemented trough SOA into the overall EA of healthcare 
information systems. Furthermore, solutions have already been considered for the design 
of applications, that run on mobile devices and help doctors display images and infor-
mation about health records. These solutions can be managed through a multi-layered 
SOA. It is essential to organize healthcare information assets in order to achieve the great-
est efficiency and effectivity of resources available to healthcare organizations through 
SOA. Sahi et al. (2017) and Midha (2017) state that healthcare information systems and 
ERP systems are unable to answer some of the sensitive questions, regarding personal 
healthcare data. Sahi et al. (2017) and Midha’s (2017) reports also underline the relation-
ship between two aspects: confidentiality and user trust. Privacy regulation ensures con-
fidentiality of patient’s data. It accelerates the adoption of healthcare informatics and 
eHealthcare solutions, increasing the level of trust from patients 
The software manufacturers claim to be aware of applicable legislation and infor-
mation security requirements. Such that it takes all necessary actions to achieve and con-
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tinuously enhance compliance with state-of-the-art standards. Risk management structur-
ally identifies and analyzes potential information security breaches and manages the re-
quired preventive and corrective measures. Software development is documented in all 
stages of design and development. The technical files are concrete evidence of work prac-
tices and the quality of the product and serve the scrutiny of internal and external audits 
to claim compliance with a specific standard. Harmonized standard practices can be ad-
hered to build a trustworthy relationship with the healthcare organization and medical 
software provider. 
1.3 Managing software impact  
In society, software impact can be measured based on the how critical are the activities 
it serves and how big is the instalation and deployment scale. Clinical decision is a critical 
aspect in healthcare organizations. Decision control becoming part of automated software 
design instead of manual control, therefore pushing for risky decisions to be managed by 
software. Therefore, the need for safety-critical software. The volume in which software 
is installed defines the deployment scale. When software has a wider install base it be-
comes more relevant to society. The volume of sales given also judges economic success 
by the fact that the cost of software reproduction and distribution is zero. 
1.3.1 Control software & safety-critical software 
The importance of software in society is increasing rapidly. Moreover, control and 
critical decisions are entrusted to software systems. According to the research performed 
by (Rutkowski, 2017). the growth of software systems is typically around 20% per year. 
The growth of safety of control related software systems however is only 10%, even 
though the importance of software in society is increasing. This discrepancy is increasing 
(rep) while trying to close the gap between demand and supply for control related systems 
with software solutions that are not dealing with critical risks and lacking defensive cod-
ing techniques. Instead, the control remains with software systems on critical aspects, 
leading to unwanted risks and dangers in society. 
A clear distinction between typical software and control software can be observed in 
development and implementation. Safety-critical elements in control software are in de-
tail acknowledged in the design phase. Error, failure scenarios should be well documented 
and known. The design and code are tested extensively so failure scenarios are avoided 
at all cost. Safety-critical engineering is a good practice in software development when 
dealing with control software. 
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Medical software can harm patients and should therefore be treated in a similar way 
for example as flight management systems. The risk category can be considered similar 
to software developed for navigating air flight shuttles, flight management systems, and 
train traffic control by measuring the impact on healthcare informatics. Because of the 
risks involved in healthcare informatics on patient harm, the same type of defensive cod-
ing practices is used to protect the systems from unpredictable errors that can put patients’ 
lives at risk. Constructing defensive coding involves exponential growth of lines of code 
(LOC) in comparison with the typical coding of software. 
Over the past 40 years, the amount of code used for flight and land procedures for 
spacecraft’s on Mars has grown exponentially. The improvement in defensive coding 
practices and new coding standards in air flight control software: 
• 1975: the Viking landers had about 5 KLOC onboard, 
• 1998 Pathfinder had 150 KLOC, 
• 2003 the Phoenix lander had 300 KLOC, 
• 2004 the Mars exploration rovers each had 650 KLOC 
• 2012 the Mars Science Laboratory (MSL) Rover had 3 MLOC. 
At first glance, the connection between landing a spacecraft on Mars and how 
Healthcare Informatics works is not evident. Preventing, detecting, and containing are the 
three main control process principles in the creation of control software. However, most 
software development projects use coding standards for a different approach. In usual 
software development, some of the coding standard are ignored to increase the time to 
market, issues mitigated by the deployment of patches. As is often the situation with other 
coding standards. Regulations and standards cannot be quietly ignored when considering 
defensive coding and safety-critical software. Apart from the coding skills, software de-
velopers need to understand how air flight operates in real life. Software risk-defensive 
programming skills become mandatory in control software (Holzmann, 2013).  
Having risks mitigated in the prevention phase proves to be a successful strategy with 
fewer risks to manage in the later stages. Risk profile tables are used to store the identified 
risk behaviors based of the usability scenarios for the software product. Based on the risk 
profile, it is mandatory to mitigate the main critical risks in the design phase. After the 
mitigation of the main risks, residual risks remain unaddressed. The residual risks are also 
addressed by mandatory mitigation actions, until the risk benefit ratio gives a green light. 
In the detection phase, the risks and vulnerabilities present in the code must be identi-
fied as early as possible in the development cycle. The code is as good as the testing and 
code review. As an example, in the air flight control software for the Rover landing on 
Mars, 80% of peer review and comments were accepted and reviewed (Hevner, 2004). 
All the accepted peer reviews and comments had an immediate action assigned to them. 
For a single instance of the module of the software flight control, 10,000 peer comments 
for the process were produced with 25,000 tool reports in the detection phase.  
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The code was tested; Routine checks were conducted for common types of coding 
errors. Compliance issues with the coding standard or risky code patterns were identified.  
Defensive coding makes also testing very difficult because it prepares the system to 
react to unpredictable errors: 
• ensuring the reliability of the last instance of any large and complex software 
application 
• building defensive actions enforce containment around the residual risk, con-
taining it not to spread to other modules 
• building redundancy in the software  
• limiting software subsystems to critical action modules 
• giving the second chance to control a critical switch with code that is different 
from the one used in the previous instance 
There are no notable problems reported in air flight control caused by software prob-
lems, therefore defensive coding principles prove to be the solution when dealing with 
critical control and safety issues.  
1.3.2 Volume and economy of scale 
If impact can be measured by the critical/risk profile it operates in, the impact of soft-
ware can be measured by the amount and volume of software deployed around the world. 
Hence, the more the spread the higher the relevance for society. If the relevance for con-
trol software for airspace maybe very specific, error-proof and safe, only some submod-
ules of the software systems can be reused for future airspace control systems. When 
considering reusing systems for different scenario, the chance to scale-up is limited. 
Mostly, because every air flight routine is different to the previous one. To deploy the 
same air flight control software, it has no relevance beyond the initial scenario build.  
The software's affordability stimulates its relevance, the smaller the installation base, 
the higher the development cost per usage. The installation base must therefore be in-
creased to make the software affordable. The result is that software as a business becomes 
more profitable. Economically, it makes sense to increase its volume deployment as soft-
ware replication costs are close to zero. Increasing the installation base is can also be 
prerequisite of innovation. Although the software may well be technically clever and 
functional, it simply cannot work economically without amplifying the volume for soft-
ware especially for its subsequent maintenance. 
However, amplifying the volume of software requires a different approach concerning 
the risk profile compared to critical safety software systems. This risk is even growing 
when enlarging the install base. Usually, a software bug comes with multiple not when 
considering volumes. If the error happens for one user, it is likely to happen for more 
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users. Let us consider this scenario, if a software has a user base of 100,000 subscribers 
and a probability of a software bug appearing of 5%, for sure 5,000 of those users will 
get the software error. In addition, if that error is critical and generates collateral damage 
and harm, liability will arise. These liabilities have an immediate effect on the business 
side. In the next subchapter, three cases of liability outcomes are described. 
1.4 Case considerations malfunctions of safety-critical software  
Safety-critical software has always been seen as automatically requiring higher stand-
ards throughout all development stages; from gathering the requirements, to carefully 
building the specifications, developing and implementing the software. Similarly, the ver-
ification and validation procedures are rigorous and following the desired safety-critical 
behavior, taking into consideration time and cost.  
Moreover, a straightforward, seemingly harmless system can lead to life-threatening 
circumstances when used in a critical chain. For example, in flight control software, it 
could lead to plane crashes and life losses. Whereas, in healthcare, it could lead to a pos-
sible delay with a critical treatment. Imagine a hospital information system that does not 
notify a patient to follow-up to a critical consult, or a medical robot that malfunctions, 
this puts the patient’s life at risk. In both cases, the risk escalates because of the wide 
install base of such software.  
In the usual development process, the software can be patched on a constant basis, 
without much emphasis on quality upfront. Improving the quality of an imperative prod-
uct becomes life-practice during its lifecycle by patch working. In addition, when adopt-
ing agile management practices, it is very relevant for software engineering teams to face 
the challenges of constant improvement with limited iterations and requirements. Next, 
the question for safety-critical software systems regards the patching aspect. In contrast 
to conventional delivery times of a software patch, which can be measured even in hours, 
the switch to safety-critical software will generally require re-entering of the certification 
cycle, especially after a fatal accident. It is a time-consuming, and sometimes expensive, 
process, which is definitely not quickly fixed. 
This section addresses problematic implementation of software that led to a mass recall 
of products, closing business units and catastrophic outcomes.  
First three cases are introduced:  
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1.4.1 CASE 1: Boeing 737 MAX flight control software malfunction  
In the 50 years since its first flight, the Boeing 737 MAX had an exceptional safety 
record. Recently, Boeing opted to introduce fuel-efficient engines for the model 737 
MAX. The change resulted in a weight redistribution of the plane. Instead of redesigning 
the fuselage to generate a proper weight distribution, Boeing introduced a flight control 
software module assisting the landing procedure for stabilizing the plane. However, be-
cause of a landing sensor failure and a software design error, the pilots lost control of the 
plane while stalling. Investigators confirmed that the transmitted information from a sin-
gle sensor, in both accidents, caused the flight control system to strongly descent the jet's 
nose, ultimately leading to a steep, deadly dive. Simultaneously, because of the software 
error, pilots could not take control of the plane, resulting in the loss of 346 lives in two 
different plane crashes. Important now is how the engineering lessons of failing safety-
critical systems are integrated into the software industry, to prevent catastrophic out-
comes.   
Authorities explained that Boeing, during the certification procedures, disregarded the 
automated stall prevention feature as a critical system that could lead to potential loss of 
life. Classifying the stall-prevention behaviors as a critical feature would have led to fur-
ther scrutiny. If engineers and mid-level managers referred to Boeing's early classification 
for security and critical behavior with more scrutiny, these automatically potential risks 
would have been further analyzed. Whereby mitigation actions could have been arranged 
to handle those specific risks. 
Eventually, the Boeing aircraft fleet was grounded until the software issue was re-
solved. In the process of grounding the fleet, 1 billion dollars in terms of losses were 
registered. Note, any time or money investment for identifying such critical behaviors 
beforehand would have saved lives and be exponentially cheaper than handling it after-
wards.  
1.4.2 CASE 2: Medtronic chamber pacemakers recall 
Because of the extensive volume of the install base in healthcare informatics, safety 
control software errors can pose threats and higher liabilities. 
Reading the information that the FOOD and Drug Administration (FDA) published in 
January 2019, Medtronic, Inc. Dual Chamber Implantable Pulse Generators (IPGs) had 
to be recalled from the market. The IPGs are implanted cardiac pacemakers, which pro-
vide stimulation to increase the heartrate of patients with a slow heart rhythm (bradycar-
dia) or no heart rhythm. In Figure 1. Medtronic has issued an urgent medical device recall 
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and distribution suspension for the dual chamber peacemakers, which had a worldwide 
coverage.  
 
 
Figure 1 : Medtronic press release - pacemaker recall 2019 
The pulse generator is the small implanted unit containing the battery and other elec-
tronic parts. These devices are designed to be used in addition to routine clinical moni-
toring by a health care professional. The reason for the recall stated was: “due to the 
possibility of a software error that can result in a lack of pacing. Patients and physicians 
cannot predict whether and when this software error might occur. A lack of pacing 
could result in patients experiencing slow heart beating, low blood pressure, and symp-
toms such as lightheadedness, fainting, and even death.” 
 When an implantable device can malfunction because of a software issue, and can 
lead to a patient’s death, the issue becomes severe. Medtronic had to recall 13,440 de-
vices distributed throughout the United States. They stated that a software update was 
developed, which could be installed on affected devices to correct the issue. Meanwhile, 
Medtronic requested doctors to return all unused and unopened devices. Moreover, they 
warned patients if new or unexpected symptoms appeared with a pause in pacing, they 
should immediately approach their usual medical care. Medtronic was obliged to pro-
vide mitigation actions towards this issue. Note, since they could not provide remote 
servicing, they had to recall products of the market and make the issue public to safe-
guard the patient’s wellbeing.  
1.4.3 CASE 3: Philips Cleveland FDA investigation 
Furthermore, Philips Cleveland has put patients’ lives at risk by medical software 
and products manifesting malfunctions. In this case, when the FDA intervened, with 
more drastic measures to the point that the Philips Cleveland business unit had to be 
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closed. Therefore, the focus within Philips Cleveland switched to training and research 
only (FDA, 2019). 
According to the report from FDA, there were 133.845 complaints. 97% complaints 
were closed based on the assigned hazard harm matrix symptom codes. From the 3,623 
remaining complaints, 1,792 of these should have been transferred to Philips complaint 
handling unit for further investigation based on the company's own work instructions.  
The 2017 report was only the endpoint of a series of reports issued by the FDA that 
concerned the Philips mitigation of risks and quality aspects at the Cleveland production 
facility. Even if Philips continuously invested to improve these aspects, it served as a 
valuable lesson, regarding implementation of software medical devices. In the process, 
Philips improved the quality systems, and their procedures and accountability in the pro-
cess when dealing with the extensive number of nonconformities. Philips learned to use 
these lessons across the company worldwide; therefor the failure to reach the high quality 
that Philips is known for, generated other winning scenarios. To deal with the reputation 
loss, in 2017 after a long history of nonconformities, Philips had to take drastic measures 
to the point of closing the production facility and focus only on research and development 
in Cleveland.  
In Figure 2, you can observe the first page of the 2017 FDA report that contained 18 
pages, describing quality control issues and various other nonconformities, which could 
lead to potential serious injuries or potential death.  
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Figure 2 : FDA Investigation report for Philips Cleveland 
 
Software issues generated recalls, in the Philips Cleveland case. In the indicated sam-
ple, there were 1890 Tomography X-ray systems with the same deployed software bug, 
with class II recall action. This generated an extensive recall strategy based on quality 
and software related developments. 
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Figure 3 : Philips Cleveland FDA recall - software design cause 
The firm’s diagnostic imaging manufacturing operations in Cleveland “currently make 
up less than 3% of the total global diagnostic imaging sales volume, ceased fully in the 
second half of 2018. Philips now plans on investing in a new R&D facility in Cleveland.” 
(Philips, 2018) according to Steve Klink. As Philips retains a high standard towards its 
products, and because of the extensive losses in the Cleveland business unit, the manage-
ment in Philips decided to close the business unit altogether and focus only on the R&D 
Facility.  
1.4.4 Impact - FDA Volume recall analysis for software 
When a company learns that one of its medical devices is problematic on the US mar-
ket. it offers correction or removal, depending on the nature of the recall action to be taken 
by the supplier, and requires so before FDA needs to do an investigation about the filed 
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complaint. This response is related to the internal customer service process that the 
company has in place. 
The company has either the possibility to perform correction actions that address a 
signaled problem with a medical device that is being used or has been sold. Alternatively, 
it has the possibility to remove the medical device from the customer premises, or at the 
same location.  
FDA uses the term "recall" to address a problem with medical devices, which violate 
the FDA law when a manufacturer takes correction or removal measures. Recalls occur 
if the medical devices are faulty, if they may be a health risk, or if they are both faulty 
and retain a potential health risk.  
Recalling a medical device does not always imply that you have to stop using the prod-
uct or the mandatory action to return the product to the manufacturer. Recall sometimes 
involves the checking, adjustment, or fixing of the medical device. The FDA may legally 
require an enterprise to retract a device. This could be the case if an enterprise continues 
to refuse to recall a device linked to serious health problems or death. 
Class I: A situation where there is a reasonable chance that a product will cause seri-
ous health problems or death. 
Class II: A situation where a product may cause a temporary or reversible health prob-
lem or where there is a slight chance that it will cause serious health problems or death. 
Class III: A situation where a product is not likely to cause any health problem or 
injury. 
Let us consider the following analysis made using data offered by the U.S. Department 
of Health & Human services portal, from the FDA Section provided information for med-
ical device recalls.  
The database can be filtered by Product Name, Product Code, Recall Class, Recall 
Date, Recall Number, Reasons for Recall, Recalling Firm, and Root Cause. Based on the 
patient harm, classes were introduced, to classify the 3 scenarios. Each of the recall for 
software issues had an essential identified root cause. There were five identified root 
causes by software: Software Design, Software Design Change, Software Design Change 
in the Manufacturing Process, Software Change Control, and Software in the Use Envi-
ronment.  
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Figure 4 : FDA class distribution of software recalls 
The sum of the total software issues related recalls by FDA equals 859 recalls. From 
the 859 recalls, only 21 were for minor reasons that would not lead to patient harm. The 
828 recalls were being identified as class 2. These recalls concerned software problems 
that would lead to short-term health problems, with a minor chance to cause serious injury 
or death. The last 10 recalls were being identified as class 1, due to the chance to lead to 
health damage or loss of life. Another aspect that should be considered, because of the 
economy of scales, is that the software issues can be traced to several thousand devices. 
Only one instance for a software recall is traced to all the devices on which the software 
was installed, which in some cases implies tremendous post sale costs for the mitigation 
actions. 
1.5 Philips VitalHealth company profile and products 
 
Philips leverages its rich heritage of innovation as one of the world’s largest developers 
of healthcare technology. For the overall sales volume, EUR 1.7 billion are dedicated to 
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research, supporting 7,000+ engineers in development of future technology enabled 
healthcare solutions. 
“Philips acquired VitalHealth Software, a software company whose mission is to con-
tribute to the improvement of global healthcare through innovative IT-solutions. For that 
purpose, a platform has been developed which has large potential within healthcare or-
ganizations. VitalHealth Software was founded in 2006 by Mayo Clinic (USA) and Noa-
ber Foundation (the Netherlands). The company was founded to develop game changing 
cloud-based eHealth solutions with emphasis on solutions for people with chronic dis-
eases such as Diabetes, COPD, CHF, Depression, Cancer and Alzheimer's.”    
(VitalHealth, 2019) 
.  
 
Figure 5 : VitalHealth platform 
To enable team-based population health, Philips proposes to introduce an end-to-end 
population health management and care suite of software, VitalHealth, for all care-related 
interactions with the individual, as well as for population analytics and stratification, and 
outcomes tracking and management. VitalHealth is currently used by 6 million patients 
and 132,000 professionals across more than 170 provider networks around the globe. 
Philips VitalHealth has customers in the United States, the Netherlands, China, Sweden, 
Finland, India, France and Belgium.  
VitalHealth consists of solutions covering four focus areas:  
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1) Patient and clinician engagement, (ENGAGE) 
2) Care coordination, (COORDINATE) 
3) Outcome measurement & management (QUEST LINK) 
4) Population Analytics. (INSIGHT) 
 
 
 
Figure 6 : Philips VitalHealth products 
1.5.1 ENGAGE - Patient and clinician engagement 
“The VitalHealth solutions encourage patient engagement through use of interface 
with a base EMR patient portal or use of the VitalHealth patient portal. Individualized 
care plans, based upon best practice care paths, include a set of activities that can be 
automatically assigned to the patient. These activities are based upon the goals of the 
patient. Completion of activities/tasks and progress towards individualized goals can be 
automatically assed with alerts/reminders sent to the patient or their care giver” (Vi-
talHealth, 2019). 
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Figure 7 : Population health management portal 
Features: 
• Potential to determine the degree of patient activation at the onset of their care 
• Continuous automatic monitoring of the individual patient’s response to assign-
ment  
• Remote self-monitoring with functionality to record patient specific data 
• Integrated for easy online collaboration between professional and patient 
• User friendly interfaces for use of mobile devices 
• Personalized (online) education 
 
 
Figure 8 : Patient portal 
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“The VitalHealth Patient Engagement solutions ensure that patients participate in a 
timely manner in shared decision-making, supporting better health outcomes. These so-
lutions support the assignment of individualized care plans based upon best practice care 
pathways and patient preferences. Shared decision-making is supported leading to higher 
levels of patient engagement and improved outcomes” (VitalHealth, 2019). 
1.5.2 COORDINATE - Care coordination and care management 
“The growing global burden of chronic disease is forcing providers and health care 
systems to deliver the care they provide in new ways. Communication amongst providers 
and between providers and patients is central to achieving better outcomes at lower costs. 
VitalHealth Software’s approach to Care Coordination facilitates this new paradigm of 
health care delivery – team-based care. 
VitalHealth Care Coordination facilitates integrated collaboration within multidisci-
plinary care teams. It allows for better, more effective and more transparent care for these 
patients. Our solutions support collaboration and communication between involved 
healthcare professionals and other stakeholders within the ecosystem. The automated de-
livery of reminders and alerts facilitates not only the communication between care pro-
viders but also decision support and it ensures that care givers and other stakeholders with 
appropriate expertise (e.g. fitness coach) can efficiently participate in the care process 
within the ecosystem” (VitalHealth, 2019). 
 
Figure 9 : Care coordination portal 
“Managing chronic conditions is effective and efficient with VitalHealth’s Care Coor-
dination solutions. Disease specific content, including care pathways, is available for the 
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common chronic conditions including Asthma, COPD, Diabetes, and Behavioural/Mental 
Health. The disease specific care pathways are individualized into care plans for each 
patient, with role-based assignment of tasks. This allows stakeholders to work together 
as a care team within the ecosystem to provide holistic guidance and care. The VitalHealth 
solutions include tools to improve patient engagement, individualize the manner in which 
they participate in shared decision making and provide remote monitoring” (VitalHealth, 
2019). 
Figure 10 : Population health management view 
The following are the features in this software: 
• User-friendly and easily configurable dashboards 
• Individualized and best practice-based care pathways 
• Personalized care plans 
• Built-in clinical decision support, based on (medical) guidelines 
• Referral Management 
• Care Pathways 
• Remote monitoring 
• Care team support 
• Two-way EMR integration 
• Automated rules-based evaluation of patient responses 
• Automated alerts 
1.5.3 QUESTLINK - Outcomes management 
“Outcomes are what matters to patients, providers and payers, and the overall ecosys-
tem. Recently, systems to support the efficient collection of outcomes have become even 
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more important as reimbursement has been linked to measurable outcomes. VitalHealth 
Software solutions support the efficient collection of outcomes data. The configurable 
rules based approach automates the collection of the outcomes data and use of that data 
to improve individual patient care and guide the development of the ecosystem. 
VitalHealth’s Outcomes Measurement solution supports hundreds of validated survey 
instruments. Many of these instruments are required for reimbursement by payers includ-
ing CMS. The ease, with which these surveys can be automatically sent, based upon di-
agnostic or procedural codes, helps to ensure that providers and health care systems min-
imize the administrative burden related to outcomes measurement. Outcomes data can 
also be helpful in identifying quality improvement opportunities for health care systems. 
Together we can continuously improve the care we provide” (VitalHealth, 2019). 
1.5.4 INSIGHT - population healthcare analytics 
“Population management is based upon the evaluation of outcomes for groups of de-
fined individuals. Care is delivered one patient at a time. To improve outcomes for pop-
ulations we must improve the outcomes for individuals. Therefore, VitalHealth 
Healthcare Analytics solutions enable providers and systems to both monitor individual 
outcomes and the outcomes for appropriately risk stratified populations. Our solutions 
enable health care systems to flexibly evaluate outcomes of populations which are im-
portant to the organization. This would help provide evidence-based information about 
the ecosystem and guide decision-making. 
VitalHealth Healthcare Analytics solutions offer data mining tools and process mining 
algorithms. This helps health care systems and providers improve their population health 
outcomes based upon an iterative process of evaluation of appropriately risk stratified 
groups. The process is based upon individual actionable care plans linked to flexibly con-
figured outcomes measurement” (VitalHealth, 2019). 
The following are the features in this software: 
• Risk Stratification 
• Outcome Analysis 
• Data Mining 
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1.6 Regulation requirements – European union regulatory environ-
ment 
Introduction for regulatory strategy 
Creating a better legal structure is probably the most important way to protect users 
from software abuse (Rutkowski, 2014). Regulators around the world organize to gener-
ate harmonized standards. Besides these harmonized standards, in practice, governments 
develop own country-specific regulation that software manufactures have to abide by in 
order to gain market access. The controller processes healthcare data within strict com-
pliance rules. Whereas information around health and treatment will be regarded as a 
secret. The healthcare organization is keeping individuals fully informed about the pur-
pose of sharing data for an intended purpose asking for explicit consent. Maintaining data 
securely is increasingly difficult for highly sensitive information. Therefore, update pol-
icies and procedures around the collection, storage and use of patient data becomes a 
critical practice (Fuentes 2018). Healthcare organizations handle data varying from finan-
cial records and health insurance information to patient test results and biometric infor-
mation. This data is uniquely linked to an individual and are mostly unalterable (Fuentes 
2018).  
To safeguard healthcare practices and ensure the quality and integrity of the healthcare 
act, regulation has been adopted to govern over patient rights. Regulation also dictates 
under what rules, and limits software in healthcare operates. In addition, it is important 
to specify that regulation can be region and country specific, so in order to gain market 
access, a healthcare software needs to abide by the specific regulation of that region and 
country.  
The two regions that have extensive regulation that extend to healthcare software are 
United States and Europe. FDA is the main regulator for the US. The European Commis-
sion is the regulator for the European Union. It is usually easier to gain market if you have 
a product certified in either US or Europe due to commercial agreements and harmonized 
international standards. Moreover, there are countries that have commercial international 
agreement to facilitate trade between states. When this is the case the certification process 
can be faster and cheaper, and market access becomes easier to obtain.  
Therefore, the rational to gain regulatory approvals into US and Europe, becomes a 
winning one. In this report, only the European Union Regulation was treated, given the 
fact that Philips VitalHealth products, started in the Netherlands. In addition, the scenario 
became more relevant for Philips VitalHealth because of the new changes made in the 
European regulations.  
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1.6.1 European union medical device regulation (EU MDR) 
 
In the European Union (EU), healthcare software is classified as a medical device and 
therefore must abide by medical device regulation. Philips VitalHealth has software clas-
sifiable as class 1 and 2, according to the new EU Medical Device Regulation (EU MDR). 
The EU has a medical device directive (MDD) in place that is establishing some limita-
tions and guidelines for healthcare products and medical devices. From 2020, a new pol-
icy will be applied within the EU that will regulate the medical device market with man-
datory immediate action (European Commission, 2018). EU MDR requires more con-
straints for medical devices. Therefore, it ensures more quality and safety for devices used 
in healthcare. Each country has a regulation body: Philips VitalHealth resides in the Neth-
erlands and can chose different regulators for medical devices. For the VitalHealth prod-
uct certification the choice was TÜV SÜD. TÜV SÜD has arranged a timeline that med-
ical device suppliers including Philips VitalHealth could follow while having to abide by 
the recommended deadline and practices. (TÜV SÜD, 2018) 
 
 Figure 11 : TÜV SÜD– EU MDR Milestones for Philips VitalHealth  
Milestone: May 5, 2017,  
• New medical device regulation was published with a transition period of 3 
years. 
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• Due to this fact and the fact that this regulation includes specific clinical re-
quirements which are not consistent with the EU MDR Guidance Document 
on clinical evaluation  
• In the Netherlands TÜV SÜD decided to extend the implementation timeline 
for the reflection of the state-of-the-art methods of clinical evaluation. This 
decision was taken to allow medical device manufacturers to use their re-
sources effectively when adopting the upcoming changes with the new regula-
tion to their clinical evidence documentation. 
•  extension is just possible if the requirements on clinical evaluation and active 
post-market surveillance of the applicable directive MDR 
 
Milestone: July 31, 2017 – May 25, 2020 
• Every submission can still follow the currently used methodology reflected in 
the EU MDR or another comparable method 
• Every submission shall include a plan on how to reflect the current state-of-
the-art method for clinical evaluation  
• Every technical documentation that is selected in this period shall either in-
clude a plan for the reflection of state-of-the-art methodology implementation 
as presented, for example, in the, or be part of a general plan of the manufac-
turer 
 
Milestone: May 26, 2020 
• Clinical Evaluation Report shall be reflecting the current state-of-the-art method 
of clinical evaluation by either following the EU MDR revisions or another com-
parable method 
 
In order to reach these milestones because of the complexity of the certification pro-
cess, a stepwise approach needs to be arranged focusing on the main action principles 
explained in the EU MDR document and annexes (TÜV SÜD, 2018) :  
A. Checklist against the EU MDR regulation (if applicable as a medical device)  
B. Identify class rules – conformity assessment routes in the EU MDR 
C. Identify risk level – risk profile 
D. Conformity assessment routes and essential principles  
E. Certification of the quality management system  
F. Product certifications 
G. Product lifecycle management  
 
Based on the EU MDR document and annexes, you can follow fragment statement 
from the regulation. For action A. Check against EU MDR regulation (if medical device) 
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according Philips VitalHealth product white paper Philips VitalHealth products are a 
medical (You can see underlined the reasons by which the software products become 
medical devices).  
Medical device definition 
“(1) ‘medical device’ means any instrument, apparatus, appliance, software, im-
plant, reagent, material or other article intended by the manufacturer to be used, alone 
or in combination, for human beings for one or more of the following specific medical 
purposes:  
(2) Diagnosis, prevention, monitoring, prediction, prognosis, treatment or allevia-
tion of disease, …. or compensation for, an injury or disability,  
(3) Investigation, replacement or modification of the anatomy or of a physiological or 
pathological process or state, ...” The Phillips VitalHealth software products fall into the 
class category IIa and IIb, according to annex VIII.  
 
 
Table 1 : Classification EU MDR 
 
From EU MDR regulation article 6.3. Rule 11:  
Software intended to provide information which is used to take decisions with di-
agnosis or therapeutic purposes is classified as class IIa, except if such decisions have 
an impact that may cause:  
 death or an irreversible deterioration of a person's state of health, in which case it 
is in class III; or  
 a serious deterioration of a person's state of health or a surgical intervention, in which 
case it is classified as class IIb.  
Software intended to monitor physiological processes is classified as class IIa, ex-
cept if it is intended for monitoring of vital physiological parameters, where the nature 
of variations of those parameters is such that it could result in immediate danger to 
the patient, in which case it is classified as class IIb. All other software is classified 
as class I.  
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1.6.2 Product and QMS Certifications for Philips VitalHealth  
It is crucial when thinking about product design and development to have higher stand-
ards in mind. If the product is certified against higher standards, the ability to sell and be 
compliant to client needs is strongly facilitated. The use of harmonized standards, be-
comes very relevant, because they enforce client trust on international level also making 
the regulatory approval a faster process. 
Harmonized standards are available for: 
• Quality management systems (QMS)  
• Risk management 
• Basic safety 
• Usability 
• Software development 
For the EU harmonized standards are published in the Official Journal of the EU. Harmo-
nized standards, including product standards need to be purchased (standardization or-
ganizations). At the beginning of a design and development cycle, the current regulatory 
requirement (and the customer needs/requirements) are gathered as input to the creation 
of the system requirements. Application of a harmonized standard gives the presumption 
of conformity to the Essential Requirements and GSPR.  
 
 
Figure 12 : Harmonized Standard EN ISO 13485 - QMS requirements 
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1.6.3 EU MDR Lifecycle approach 
Relationship between device lifecycle, ongoing collection and monitoring of clinical ev-
idence and requirements for vigilance and post market surveillance (PMS).  
 
Figure 13 : Lifecycle approach - BSI Whitepaper 
Two aspects to be taken into consideration, in lifecycle. The first one is related to the 
lifecycle stage: concept, design and development production postproduction and ob-
solesce. All of the above have technical documents that come out of each stage, that 
feed into the Risk-Benefit analysis. 
1.6.4 General data protection regulation (GDPR) 
Healthcare organizations inquire whether software companies comply with regulatory, 
security standards and deliver products that further allow the healthcare organization to 
comply with relevant regulatory standards and privacy laws. The healthcare organization 
becomes a data controller because it uses information systems to operate with patient 
data. The controller is the one who determines the purposes for which, and the way in 
which personal data is processed. By contrast, the software company is processing per-
sonal data on behalf of the data controller. The data processor is subject to far fewer ob-
ligations under the law. As a constant practice, the legal liability towards data subjects 
for controlling and processing patient data remains with the healthcare organization. 
Controller - The natural or legal person, public authority, agency or other body which, 
alone or jointly with others, determines the purposes and means of the processing of per-
sonal data 
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Processor - The natural or legal person, public authority, agency or other body which 
processes personal data on behalf of the controller; 
Data subject - The natural person whose data is being processed 
• Personal Data: Any information relating to an identified or identifiable natural 
person ('data subject')/ Name, date of birth, IP-address, Mac Adress; marital sta-
tus, salary, etc. 
• Special categories of personal data, racial or ethnic origin, political opinions, re-
ligious or philosophical beliefs, or trade union membership, and the processing of 
genetic data, biometric data for the purpose of uniquely identifying a natural per-
son, data concerning health or data concerning a natural person's sex life or sexual 
orientation 
According to GDPR regulations, ERP and IT systems have to maintain a refined IT 
Security and Risk Management procedures to ensure that the data is safe and not tampered 
with. GDPR enforces security measures when handling healthcare data, creating an extra 
layer of complexity over healthcare assets. Information about healthcare assets is highly 
sensitive and considered as a special category altogether (Zarsky, 2017).  
 
1.6.5 European Interoperability Framework (EIF) 
The interoperability between systems and different administrative levels is enforced 
within the EU by the European Interoperability Framework (EIF). Trust is linked with 
aspects like confidentiality, integrity, accountability, authenticity, identity, and data man-
agement. 
 
Figure 14: European interoperability framework concept 
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The renewed European Interoperability Framework (EIF) was adopted on 23 March 2017, 
approximately one year before the GDPR was applied. EIF gives specific guidance on 
how to create interoperable digital public services. It has 4 levels of interoperability, 12 
underlying principles, and 47 concrete recommendations on how to improve governance 
on their digital platforms. The four levels of interoperability consist of the legal, organi-
zational, semantic, and technical interoperability. EIF is a key instrument for establishing 
interoperable digital services not only at EU level, but also at national and regional. En-
hancing the consistency of operations among different stakeholders, trough healthcare IT, 
makes this Framework relevant to be adopted in the following years. Public administra-
tions can save time, reduce costs, increase transparency and improve the quality of ser-
vices (European Commission, 2017). Even though the EIF is just the European Commis-
sion's recommendation, the benefits of implementation incentives encourage organiza-
tions to start using the framework within their systems.  
 
1.7 Risk management & control for software in healthcare 
It is generally understood that a risk is a combination of the probability and the severity 
of the harmful issue happening. Nevertheless, it is difficult to reach common understand-
ing between various stakeholders about the application of risk management as each party 
sees various potential threats, and considers a different probability and severity to each 
threat. Regarding software in healthcare, the protection of the patient by managing the 
risk to quality must be taken as paramount, although there are many actors involved. The 
actors vary from the patient to the physicians, and the government regulation and industry 
services. 
The quality risk management is only one part of the overall risk. The quality risk com-
bined with security and privacy offer a more comprehensive risk profile for software in 
healthcare. It is important to understand that product quality should remain aligned with 
the attributes used in clinical trials during the entire product life cycle. An effective risk 
management approach for quality can also guarantee the patient the high-quality 
healthcare act. The recommended practice is a proactive way of identifying and control-
ling potential quality issues during design and development of software in healthcare. The 
use of quality risk management can further improve decision-making if there is a quality 
problem.  
In healthcare informatics there are three main types of risks identified based on the 
critical behavior that software should deliver. Security and privacy are the first two, and 
both of them enforce user trust and integrity of the medical act. The third risk is related 
to the usability of the software and the probability to generate patient harm. Identifying 
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the critical behaviors for medical software is crucial in the early design phases. As de-
scribed in the literature review, risks related to privacy and security are handled in the 
design phase. Thus, security and privacy by design come as a mandatory practice. In the 
next subchapter, mandatory regulatory aspects are discussed.  
Especially in healthcare software, the risks related to patient harm occur from the ex-
tended usage of the software itself. Usability related risk analysis is relevant to be build. 
The source of a potential hazard is identified and described, this based on the usability 
standard. All of the events, that make the hazard occur, are mapped. The hazardous situ-
ation is described and linked to the patient harm profile.  
 
 
Figure 15 : Risk control matrix for healthcare software 
The risks need to be addressed and control measures need to be established. Each risk 
is treated individually, described and provided with an identifier. First, the initial risk is 
assessed in terms of probability and severity. Next, the probability can be categorized 
in frequent, probable, occasional, remote or improbable during normal use. Additionally, 
the severity can be categorized into five levels;  
• catastrophic resulting in patient death,  
• critical resulting in permanent impairment or life-threatening injury,  
• serious resulting in injury or impairment requiring professional medical inter-
vention,  
• minor resulting in temporary injury or impairment not requiring professional 
medical intervention  
• Negligible resulting in inconvenience or temporary discomfort.  
Finally, a gateway control is put in place for acceptable and unacceptable risks. For 
the unacceptable risks, a mitigation action is assigned to them. A potential risk places the 
software in a completely different class in terms of regular consideration. The mitigation 
actions help to reduce the risks, but do not eliminate them completely. Therefore, there is 
still a residual risk that needs to be further mitigated. In some instances, the risk/benefit 
analysis can dictate if the risk is worthy to take because of the potential benefits for the 
business.  
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2 METHODOLOGY 
The methodology chosen for this research was an exploratory-explanatory case study 
based on the problem statement and three-research questions. Exploratory methods were 
used to generate an in-depth understanding of business needs and current business prac-
tices. At the same time, the explanatory methods were relevant in presenting the desired 
results and the build-up using multiple artifacts information systems (IS) that answered 
the research questions.  
As stated in the introduction, the following research questions were considered spe-
cific to the healthcare software product lifecycle: 
 
• How to stay in compliance with regulatory requirements and export controls 
during the product lifecycle? 
• How to present the regulatory regional information during the product lifecycle 
to the various stakeholders for medical serving software? 
• How to ensure strategic business architecture to validate/grow/implement/ de-
liver value-added solutions with market access in a timely manner? 
 
 The research methods used to explore the product lifecycle of Philips-VitalHealth 
were data collection and data analysis. Meetings and interviews were planned and con-
ducted on a weekly basis, to clarify and ensure the validity of the current information. 
Consistency was ensured by checking the current IS artifacts. During the interviews, an 
assessment based on the research questions was conducted for identifying new possible 
business practices.  
The Philips VitalHealth IS artifacts were identified as constructs, and methods that 
were developed and used to support the business practice. Assessment of literature, reg-
ulations and roadmaps were also included in answering the research questions. In order 
to answer the research questions, new IS artifacts needed to be constructed. Following 
design science research, executive IS artifacts were built from the emerging knowledge 
process. In addition to design science, IS behavioral science research was used to in-
quire in the organizational process. Therefore, integrating newly acquired knowledge of 
software development cycle, new market entry, market access, quality control, regula-
tory control and change control, in the IS artifact. The IS artifact, in this case resulted to 
be the masterplan for product lifecycle management. The masterplan influences deci-
sion control over several aspects of the business, also offers strategic insights for 
roadmaps and future product development.  
The aim of using the artifact, net benefits for the system service and quality of infor-
mation. During several interviews both management and development and testing, ex-
pressed interest about its utility. The interplay between business strategy, IT strategy, 
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organizational infrastructure and IS infrastructure was addressed in the artifact creation. 
Implementation in a work system the objectives, tasks, problems and opportunities which 
defines business needs as perceived by individuals in Philips VitalHealth.  
 
 
Figure 16: Strategic alignment: Leveraging information technology 
The roles, skills, and characteristics of individuals in the organization shape such per-
ceptions. In the context of corporate strategies, structures, culture and existing business 
processes, business needs were evaluated and assessed. Based on the research questions 
and the strategic alignment in Figure 16, information technology strategy mandated 
adapting to new IS artifacts to support the information systems infrastructure. 
In the data collection stage from Philips VitalHealth the existing infrastructure for 
technology, applications, communication architectures and development capabilities 
were assessed. Identifying what is needed for the business to have market access, 
knowledge about regulatory aspects to sell the product on a new market was key to de-
fining the problem statement and relevance of the research questions.  
In the early iteration of the artifacts, the insights were gathered for each of the research 
question individually. They were compiled from technical documents, product develop-
ment databases, compliance procedures, quality and regulatory requirements, legal agree-
ments, audit tables, sales practices, and various product management tools. The purpose 
of the data collection was to collect all the relevant information into a product lifecycle 
masterplan.  
This also implied gaining several layers of information with different complexity. Both 
a high-level picture and the in-depth rooted inquiry about the product lifecycle were rel-
evant. The information collected in early stages was checked and verified with the people 
responsible over the process. For product lifecycle management, the relevant stakeholders 
were identified. They varied in roles from product managers, sales managers, quality and 
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regulatory responsible, developers to product testers and external consultants. Semi-struc-
tured interviews with stakeholders were conducted that could provide valuable input on 
how product development, requirement gathering, sales process, quality and regulatory 
controls shaped the Philips-VitalHealth product lifecycle management. In addition, not 
only the internal knowledge was gathered to ensure internal validity, but also the need for 
external validity of the evidence. External consultants were interviewed in order to find 
out from notified body/regulatory perspective what requirements are in place and what 
Philips VitalHealth needs to do in order to fulfill those requirements. Harmonized stand-
ards were introduced together with the external consultant on a roadmap of compliance 
standards. Based on the feedback loop intended as a practice in design science, to answer 
the research questions, three artifacts were created, compiling the relevant data and infor-
mation. The main output was a design for a master plan for product lifecycle management 
for Philips-VitalHealth.  
Methodologies are typically rooted in behavioral science data collection and empirical 
analytical techniques. On the basis of Hevner (2004), how design science is to be under-
taken, assessed and presented, this section would describe the building of artifacts that 
answer the given problem statement. Because of the complexity issue, the problem design 
and its solution become crucial for developing an application of the artifact. 
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3 DESIGN SCIENCE 
3.1 Artifacts, research process steps 
From theory, we find out that the design science supports a problem-solving paradigm 
that continually changes the perspective of design processes and artifacts designed to the 
same difficult problem. The main two processes used in design science iteration for IS 
artifacts are built and evaluated (Hevner, 2004). 
For the three main research questions in this report, the build- evaluate loop in this 
research was iterated several times, therefor increasing the quality of the design with each 
iteration based on the required context. More iterations mean more specific integration 
and relevance for the designed IS artifacts. 
Based on the present behavior several actions are needed: First, analyzing the behavior 
in the research questions, exploring the phenomena, then researching the present truth. 
Secondly, gaining enough insight about essential requirements, market access and prod-
uct lifecycle management in market preparation. Generally, the aim of building the arti-
facts was to focus on the utility of the solution, build it and evaluate it in as many instances 
as possible. In a good design science, truth and utility are inseparable. Behavior feeds the 
design, then the design feeds the theory.  This enables the identification of the justifica-
tion/evaluation weakness internal to the artifact as well as the reassessment and refine-
ment of the artifact with each iteration of the loop.  
While in the build-evaluate loop, there was a consideration of the evolution of both the 
design process and its objects. As requirements constantly changed during the research 
process, it gradually became a creative stepwise approach.  
For the purpose of this research report, we follow several recommended steps of a 
model designed by Hevner (2004), that are to be considered when building utility and 
validity into the desired artifact.  
 
1. Design an artifact: creation of an innovative, purposeful artifact 
2. Problem relevance: description of problem domain 
3. Design evaluation: evaluation of the artifact  
4. Research contributions: novelty, innovative problem solving 
5. Research rigor: several iterations of the build – evaluate loop to ensure con-
sistency 
6. Design as a search process: tested the effectiveness of the design 
7. Communication of research: technical but also managerial audiences 
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3.2 Design an artifact: creation of an innovative, purposeful artifact 
For each of the three main research questions followed in this report a design was 
created based on the needed solution. The artifacts design was strongly linked to the ques-
tion how a complex problem can be solved in a lean way, considering the stakeholders 
involved in the product lifecycle. 
For the first research question: 
• How to stay in compliance with regulatory requirements and export controls 
during the product lifecycle? 
The first steps to answer this question were: to understand the Philips VitalHealth prod-
ucts, the essential requirements for their intended purpose and market access, the business 
needs for different regions and countries, within which standard and regulatory frame 
technical documentation would need to provide evidence and lastly, how to adapt the 
product design and development. Moving one step down form the macro-level solution, 
one has to build and evaluate an IS artifact in order to answer the research question.  
The solution design partly has regulatory controls and market access controls for the 
company’s products. In the previous stages, it was not designed to be the masterplan for 
product lifecycle management for software products in Philips-VitalHealth, but after sev-
eral iterations it became more and more relevant while continuously integrating feedback 
from the involved stakeholders. Therefore, taking into consideration the essential require-
ments for software design and configuration became very relevant for market access and 
regulatory approvals by notified bodies across the world. 
The artifact itself would fill in the organizational gap in business practice by bridging 
information together across different departments, from sales, quality and regulatory to 
product design and development. It proved serving the organization end to end. Further-
more, strategic insights can be offer by the dashboard, therefore integrating cross depart-
ment information.  
 
Table 2 : Dashboard product lifecycle management – general product info 
In Table 2, you can follow general product information about four software products 
that Philips-VitalHealth brings the most revenue, from more than 40 products. Engage, 
Questlink, Coordinate, and Insight. These four products were also presented in the intro-
duction chapter. In addition, the artifact contains several abstract levels, from which one 
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can zoom in and out of it, depending on the needed detail level. This offers the right level 
of complexity for different stakeholders to move the process onwards. Only parts of the 
artifact design were shared, and the table figure depicts the artifact version in the later 
stages after a few builds and evaluate loop iterations. Some of the boxes were left out 
blank on purpose in order to keep an adequate level of confidentiality in the process.  
 
 
Table 3 :  Product lifecycle essential requirements checklist 
Considering the complexity of the IS artifacts, the table 3 only depicts a part of the 
design used for the artifacts themselves after a few iterations. In the previous design, the 
iteration was considered for only the regulatory aspects and later for the overall require-
ments configuration list for the software product. This overall configuration list is com-
prised of the essential requirements. Second research question:  
• How to present the regulatory regional information during the product lifecycle 
to the various stakeholders for medical serving software? 
Generally, regulatory information can get extensive, as its enforcement may be spe-
cific for each region or country and executed/conducted by different institutional levels 
such as state governments or regulatory/notified bodies. In order to gain market access 
when launching a product on an international market, one has to comply with the regula-
tion of that country.  
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Knowing upfront about the complexity and overlap in compliance, can drive business 
rational. In most cases complying to country specific regulation, involves lead-times and 
regulation can dictate the way that products are designed and developed. Including those 
country specific requirements in the essential requirements a product. A first step on how 
to display regulatory information was to start the data collection process. As a constant 
practice, was inquiring the regulatory professionals if there is a database were all the reg-
ulations around the world are centralized.  
Before Philips acquired VitalHealth, the company had already invested effort into get-
ting compliant on several markets outside the Netherlands, therefor making it possible to 
already find a database with standards that are specific to software in healthcare. Philips 
has a quality & regulatory (Q&R) map that could be taken into consideration with regu-
latory controls based on the Q&R harmonized requirements additional to non-Q&R com-
pliance requirements.  
In terms of quality systems, Philips and VitalHealth were not aligned yet, which led to 
some knowledge and implementation gaps. Assessing the artifacts from both companies 
gathering the standards was the first step to be conducted. Having a broad understanding 
on which standards are applicable for software products seemed to be the best primary 
approach of bundling information and building a filter type approach based on standard 
reach.  
In the case of Philips, which does not have a long history with software in contrast to 
its history with medical devices and physical products, it was relevant to understand the 
standards they followed in the QMS procedures and how it linked to quality and regula-
tory for software. Philips’ harmonized Q&R standards, which are all applicable for soft-
ware, are described in Figure 17. As the US and Europe constitute the main markets for 
Philips, it is in the company’s interest to follow these regions’ compliance requirements. 
Heavy regulation not only appears on regional but also on country specific level, which 
requires additional information. 
As far as it concerns VitalHealth, the company had experience launching products 
within the Netherlands and only expanding to few other countries. With the prospect of 
market expansion, a new artifact had to be built that represented the regulatory standards 
for specific regions and countries. For example, language requirements can be a bottle-
neck for market entry. This includes the consideration on what languages the software 
should entail, and how the built-in languages & labeling can be tendered. Implementing 
English as user language, makes the product accessible for UK, US, Canada, Australia, 
Indian and all other countries that use English in their healthcare act. Including German 
in software and labeling, the product may be sold in Germany, Austria and Switzerland. 
Selecting languages therefore may shift the intention of where to sell and where not.  
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Figure 17 : Phillips Q&R compliance requirements for software
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Figure 18: Philips Non-Q&R compliance requirements
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Table 4 : Representation of standards for Australia for VitalHealth - part 1
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Table 5 : Representation of standards for Australia for VitalHealth - part 2 
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Research question three:  
• How to organize the business to ensure delivery of value-added solutions with 
timely market access? 
To answer the third research question based on another iteration of the build-evaluate 
loop, a second layer of detail was built within the product life cycle masterplan. Mapping 
the essential steps to undertake the necessary business architecture to fulfill the market 
access process is the main target of this section. Software configuration, a country and 
product specific checklist and the constant rechecking and communication with the sales 
as well as design and development team.  
 
 
 
Table 6 : Essential requirements checklist - Engage 
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3.3 Problem relevance: description of problem domain 
In the process of developing and building an IS artifact, the problem relevance is dic-
tated by the business needs. In the case of Philips VitalHealth, checking for the utility of 
the constructed IS artifacts was a constant practice and varied in process.  
To better understand the Environment, which is defined into IS research, three dimen-
sions have to be considered according to Hevner (2004): People, Organizations, Technol-
ogy (see Figure 19).  
 
Figure 19 : IS research framework 
People: Weekly meetings and interviews were conducted to better understand how 
people worked within the organization and build relevance for their roles based on the 
process they had to fulfill.  
Organization: There was relevance to build utility within the organization between Q&R 
and product development. Interviews were conducted with the head of Q&R and product 
owners. Product development on the other hand talked about the essential requirements, 
the change control procedure and the harmonized standards applied. In addition to the 
internal relevance, there was also an external validation point from a consultant that had 
experience with notified bodies, where the audit needed to be prepared. 
Based on the interviews and the assessment done on the present artifacts, Philips Vi-
talHealth agreed together with the Head of Quality & Regulatory to only pursue the bare 
minimum standards to be compliant. It was decided to choose another design for present-
ing the regulatory information. It was now possible to filter for specific country regula-
tions and harmonized standards as you can see in the example for Belgium in table 7. 
Additionally, a plot was created to show a lean based regulatory requirement availability.   
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Table 7 : Regulations harmonized standards table for Australia
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Figure 20 : Global compliance heat map of harmonized standards - Belgium 
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3.4 Design evaluation: evaluation of the artifact  
 
 
Figure 21 : Design science evaluation methods table 
 
The design evaluation for the Philips VitalHealth product lifecycle masterplan, and 
regulatory action-based design followed all the methods that Hevner (2004) used in his 
design science approach, mainly because the artifact needed to be evaluated in terms of 
functionality.  
After a few iterations, data consistency, process accuracy and completeness were 
reached. Methodically, I chose four out of five methods (Hevner, 2004): observational, 
analytical, testing and descriptive.  
Additionally, information reliability and usability were tested. To better explain the 
aim of using these methods was to have the evaluation loop, that built up the relevant 
inputs for reconstruction in several iterations.  
The observational case study was used as a method, by studying the behavior of the 
artefact in business environment at the conjunction of Q&R, product development and 
sales.  
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In interviews with the Q&R and Sales a static analysis was conducted examining the 
complexity needed around the required knowledge. In addition, several iterations were 
performed on the artifact to ensure optimization of the desired behavior:  For the export 
control part, three artefacts that were previously used were now integrated into one dash-
board with the support of Q&R and commercial control. 
Based on input from the external consultant with a notified body perspective, Q&R 
acquired knowledge on business practice, building arguments to prove the utility of 
changing the internal business process in order to comply with different audits.  
3.5 Research contributions: novelty, innovative problem solving 
One of the unsolved problems was regulatory and export control wile in the develop-
ment process, that could either stall or stop the overall process in sales and product de-
velopment.  
According to design science, the artifact must represent a reality and should be imple-
mentable (Hevner, 2004). At the beginning of the research, there was no specific artifact, 
that could generate the overview about market access and regulatory control. The then 
needed meeting and call to push for activity introduced a lag in the overall process. Again, 
I started a data gathering process at the conjunction between Q&R and export control.   
For each of the products there are different regulatory processes and intercountry 
agreements that need to be taken into consideration: i.e. in Iran shipment is not allowed, 
whereas if the risk-benefit analysis proved positive for Austria, the export and regulatory 
control would put the activity IP. Given the scope and behavior needed, each product 
contained a different risk profile.  
 
 
Table 8 : Product - global approbation matrix - market access 
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Table 9 : Approval status legend 
3.6 Research rigor: preparations for the build – evaluate loop  
Choosing several businesses that had previously been in the same spot as Philips Vi-
talHealth accounts for research rigor.  
Having knowledge on what standards to build compliance first helps in generating a 
winning strategy with the least costs involved. The decision of certifying first against EU 
regulation, harmonized standards and the US market, supports gaining competitive ad-
vantage. An external consultant with international expertise was employed and used for 
referencing to theories and business practices while the Q&R team underwent training.  
In those trainings the Q&R team was involved and trained in such a way that the team 
could scale the provided training for the whole organization. The training were to be de-
signed in such a way that they would build up a critical mass of people that can lead the 
change of a controlled practice in market access and product development. 
There was utility in having such a dashboard with the overview over the product lifecy-
cle management, with the rigor of a previous proven development based on point of view 
of notified bodies. 
In the case of Australia, one can only present products to potential customer, once the 
product has been proved compliant with the Australian market. It was therefore necessary 
to figure out which was the fastest way to get compliant to the Australian market and how 
to reach a protocol with the Australian healthcare provider. This required the acquisition 
of knowledge about the certification process.  
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Figure 22 : Australian regulatory roadmap for medical devices 
After gaining knowledge about the harmonized standards in the Australian reg-
ulation, the regulatory team started to work with product development to have the reg-
istration process in place. As you can see in Figure 22, Australia has a different classi-
fication system compared to the Europe and US, henceforth the study of the regulation 
is a timely and thorough process. The utility of having control over this aspect in a de-
velopment process becomes mandatory. 
 
3.7 Design as a search process: effectiveness of the design - Itera-
tions 
 
 
Figure 23 : Build evaluate loop 
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Design science is inherently iterative. The research questions were inherently an-
swered by having several iterations including knowledge base efforts, previously used 
artifacts and interviewing the relevant stakeholders. Putting effort into several iterations 
based on interest, relevance, optimization and utility resulted in a more effective solution. 
3.8 Communication of research: technical but also managerial au-
diences 
 
A challenging aspect was how to communicate the rather complex solution to different 
audiences. It proved suitable to create two layers of complexity within the masterplan for 
product lifecycle management. Based on the department to be addressed its purpose was 
communicated in different manners. The first level of complexity presents a high-level 
abstract with control measures used on managerial level, in Q&R and Sales. The second 
layer of complexity serves as a source for each product’s essential requirements whereas 
the design team acknowledges the requirements and decide for a plan to deal with them, 
in most of the cases elements from the essential requirements checklist become part of 
the product documentation and serve the intended technical audience.   
The design aims to develop innovative solutions, which define ideas, practices, tech-
nical capacities, and products, that can effectively and efficiently stimulate critical think-
ing in analyzing, designing, implementation, managing and using information systems. 
However, design of useful artifacts is complex among IS practitioners, because there is 
need for creative progress in fields where current theory is often not adequate. 
Having both audiences in mind, the top down and bottom up approach can funnel con-
gruent efforts and build up to a successful implementation of requirements into the soft-
ware.  
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4 CONCLUSIONS  
 
For the conclusions chapter let us reconsider the research questions.  
• How to stay in compliance with regulatory requirements and export controls 
during the product lifecycle for medical software? 
• How to present the regulatory regional information during the product lifecycle 
to the various stakeholders? 
• How to organize the business to ensure delivery of value-added solutions with 
timely market access? 
Most attention was paid to the first and second research question. The data needed to 
stay compliant was collected and presented by means of an IS artefact to the stakeholders. 
Using the design science approach relevance and utility was built into the IS artefact 
which made it to a masterplan for product lifecycle management. 
The third research question is one that has to be answered in daily practice. However, 
it is clear that not complying to the required processes for safety critical software can 
have serious consequences, as has been experienced by Philips in the past and Boeing as 
we speak. 
Presenting all the regulatory information in an actionable way is a necessity to put it 
to use by business and engineering people within a company. The regulatory information 
has to be communicated and adapted for different audiences both managerial and tech-
nical. The recommended action is to treat certain regulatory aspects by design. Identifying 
the key harmonized standards for software in healthcare and having a clear view in the 
early stages on how to stay compliant becomes a winning strategy. For software in 
healthcare it is imperative to treat security and privacy by design, safeguarding patient’s 
data.  
Having a set of harmonized standards on which the product is minimum compliant, 
makes the process of gaining approval from the country notified body faster. The process 
of gaining market access is more rapid because of less design & development time and 
more quality already built in the software products. Including harmonized standards for 
each of the products builds up a more robust portfolio of products. Therefore, applications 
towards the notified body can be submitted for a family of products not only for individual 
products. If applications are sent for a family of products the cost is depending on the 
countries specific requirements but in most cases is decreased drastically. 
Quality and regulatory, must have a role and be in control at key milestones in devel-
opment a release of a safety critical software product. Therefore, making a regulatory 
plan and an actionable dashboard where all the above-mentioned controls such as config-
uration control, change control, regulatory control, export control, are displayed is cer-
tainly relevant from the product lifecycle perspective. 
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5 LIMITATIONS & FUTURE RESEARCH 
 
There were 3 major limitations identified when doing the design science research re-
port. All of them serve as a basis for future research. Design science offers an extensive 
level of freedom by its method approach. In the design & implementation of IS artefacts 
various technologies can be used to achieve effectiveness between stakeholders.  
The environment conditioned a technology limitation while doing the research. Vi-
talHealth was acquired by Philips at the end of 2017. When this research report was in 
the final stage, the company was in the middle of the transition period between the IS 
systems. VitalHealth already had been using own procedures and IS Systems that made 
them successful in the past, but they were undergoing internal changes to adapt to the 
Philips practices. At the moment when VitalHealth had to choose the type of tooling to 
construct the masterplan for product lifecycle management, Power BI and SAP were con-
sidered. In the end the tooling was not available due to delays in transitional changes 
which led to the choice of building the design for regulatory control and market access in 
excel instead. 
This research helped with the initial design and implementation of the IS artefact and 
serves for the future transition to SAP systems. The SAP system can provide an auto-
mated version of the same design rationale. An interesting aspect to follow by future 
research will be the transition to SAP automating market access, regulatory control, and 
change control. 
The second limitation comes from the lack of possibility to observe the IS artifact in 
the actual field. Future research can focus on monitoring the behavior of the IS artefact 
in multiple projects.  
The third limitation was given by the lack of functional and structural testing, from a 
black box and white box perspective. It would be interesting to see if the interface used 
in the design is intuitive enough or whether training needs to be done to implement it. 
Ultimately, the structural test would be an interesting aspect to follow, based on the im-
plementation and the paths it provides by syncing Q&R with Product Development and 
Sales.  
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